Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Cyclophosphamide 911 Carboplatin 788 pembrolizumab 749 Paclitaxel 745 Bevacizumab 717 Cisplatin 709 Gemcitabine 621 Docetaxel 585 Rituximab 559 Radiotherapy 548 Dexamethasone 512 Nivolumab 492 Doxorubicin 446 Fluorouracil 392 Capecitabine 382 Etoposide 358 Pemetrexed 339 Cytarabine 335 Oxaliplatin 335 Lenalidomide 328 Prednisone 328 Erlotinib Hydrochloride 323 fludarabine phosphate 316 Trastuzumab 305 Leucovorin 299 fludarabine 296 Vincristine 288 Bortezomib 284 Filgrastim 284 Cetuximab 277

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × ASTX029 × Clear all

NCT03520075 2025-07-03

Study of ASTX029 in Subjects With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed

192 enrolled 56 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡